Urovant Sciences
Presence
Urovant Sciences is owned by Sumitovant.
Sumitomo Chemical is one of the...
Sumitomo Chemical is a company listed under the stock ticker 4005 (JP).
Sumitomo Chemical has a direct presence in 7 countries.Sumitomo Chemical has 29 subsidiaries including Altavant, Aruvant and Asahi Chemical.
They are in:
- Biotechnology53%
- Chemicals20%
- Other27%
Executives
View the org chart displaying its 16 main executives
Most searched biographies at Urovant Sciences
- James Robinson, Director, President and Chief Executive Officer
- Shigeyuki Nishinaka, Director
- Myrtle Potter, Chairman of the Board
Popular executive movements at Urovant Sciences
- Ted Chan, who was Vice President of Associate General Counsel, Intellectual Property, is promoted to Senior Vice President of Associate General Counsel, Intellectual Property (posted on October 19 2021).
- Laura Pala Genatossio has joined the company as Senior Vice President and General Manager, Europe (posted on October 19 2021).
- Alana Darden Powell, who was Executive Director, Business Unit Operations, Communications and Alliance Management, is promoted to Vice President, Corporate Communications (posted on October 19 2021).
Create an alert
to follow the executive moves at Urovant Sciences.
Biotechnology
Sumitomo Chemical has 2,011 competitors including Neptune Wellness Solutions (Canada), Inivata (United States (USA)) and Adma Biologics (United States (USA)).
Popular M&A news in Biotechnology
- Innoviva has announced the acquisition of Entasis Therapeutics (posted on May 24 2022).
- Remix Therapeutics has just announced a $70 Million fundraising. (posted on May 19 2022).
- Kriya Therapeutics has just announced a $270 Million fundraising. (posted on May 19 2022).
Popular contacts in Biotechnology
News
Press releases by Urovant Sciences
- Urovant Sciences® presents new data from EMPOWUR study, advancing knowledge of the treatment of overactive bladder at the 2022 American Urological Association Meeting | Urovant Sciences
- Urovant Sciences® Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints at 2022 American Urological Association Meeting | Urovant Sciences
- Urovant Sciences Announces Publication of New Review of Efficacy and Safety Data for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients in the Journal Therapeutics and Clinical Risk Management | Urovant Sciences
- Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 2022 American Urological Association Annual Meeting | Uro
- Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902 | Urovant Sciences
- Urovant Sciences Announces Appointment of Sef Kurstjens as Executive Vice President and Chief Medical Officer | Urovant Sciences
- Urovant Sciences Announces Publication of EMPOWUR Trial Subgroup Analysis Showing Similar Efficacy for GEMTESA® (Vibegron) 75mg in Dry and Wet Overactive Bladder Populations | Urovant Sciences
- Urovant Sciences Presents Positive Ambulatory Blood Pressure Data Showing That GEMTESA® (vibegron) 75 mg in Overactive Bladder Was Not Associated with Statistically Significant or Clinically Meaningful Effects on Blood Pressure or Heart Rate | Urovant Sci
- Urovant Sciences to Present New Ambulatory Blood Pressure Data in Patients Dosed With GEMTESA® (vibegron) 75 mg for Overactive Bladder at the Virtual 2021 Annual Meeting of the American Urological Association | Urovant Sciences
- Urovant Sciences to Present New Ambulatory Blood Pressure Data in Patients Dosed With GEMTESA® (vibegron) 75 mg for Overactive Bladder at the 2021 Annual Meeting of the American Urological Association | Urovant Sciences
- View more press releases Close
Social media about Urovant Sciences
- Urovant Sciences on Wikipedia, Google News & Yahoo Finance
- Urovant Sciences on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including James Robinson 
Call Urovant Sciences at +1 949...
